The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
Drugs & Targets

FDA approves Ziihera for HER2+ biliary tract cancer

FDA accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. Ziihera was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The phase III HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Drugs & Targets

FDA approves first companion diagnostic for lung cancer drug

FDA has approved FoundationOne Liquid CDx to be used as a companion diagnostic for Tepmetko (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. Tepmetko received accelerated approval from FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for Tepmetko.
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account